These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26237184)

  • 1. Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients.
    Hareedy MS; El Desoky ES; Woillard JB; Thabet RH; Ali AM; Marquet P; Picard N
    Pharmacogenomics; 2015; 16(10):1119-34. PubMed ID: 26237184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
    Stocco G; Crews KR; Evans WE
    Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
    Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
    Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.
    Gabor KM; Schermann G; Lautner-Csorba O; Rarosi F; Erdelyi DJ; Endreffy E; Berek K; Bartyik K; Bereczki C; Szalai C; Semsei AF
    Pediatr Blood Cancer; 2015 Apr; 62(4):622-8. PubMed ID: 25557962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.
    Wan Rosalina WR; Teh LK; Mohamad N; Nasir A; Yusoff R; Baba AA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):237-41. PubMed ID: 21545474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia.
    Tumer TB; Ulusoy G; Adali O; Sahin G; Gozdasoglu S; Arinç E
    Am J Hematol; 2007 Oct; 82(10):906-10. PubMed ID: 17617792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia.
    Choi R; Sohn I; Kim MJ; Woo HI; Lee JW; Ma Y; Yi ES; Koo HH; Lee SY
    Br J Clin Pharmacol; 2019 Jul; 85(7):1585-1597. PubMed ID: 30927276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia.
    Kim H; Seo H; Park Y; Min BJ; Seo ME; Park KD; Shin HY; Kim JH; Kang HJ
    Cancer Res Treat; 2018 Jul; 50(3):823-834. PubMed ID: 28882023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy.
    Smid A; Karas-Kuzelicki N; Jazbec J; Mlinaric-Rascan I
    Sci Rep; 2016 Jul; 6():30244. PubMed ID: 27452984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.
    Matimba A; Li F; Livshits A; Cartwright CS; Scully S; Fridley BL; Jenkins G; Batzler A; Wang L; Weinshilboum R; Lennard L
    Pharmacogenomics; 2014 Mar; 15(4):433-47. PubMed ID: 24624911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.
    Stocco G; Cheok MH; Crews KR; Dervieux T; French D; Pei D; Yang W; Cheng C; Pui CH; Relling MV; Evans WE
    Clin Pharmacol Ther; 2009 Feb; 85(2):164-72. PubMed ID: 18685564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of ITPA gene polymorphisms in Iranian patients with acute lymphoblastic leukemia and prediction of its myelosuppressive effects.
    Azimi F; Mortazavi Y; Alavi S; Khalili M; Ramazani A
    Leuk Res; 2015 Oct; 39(10):1048-54. PubMed ID: 26242828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Susceptibility to 6-mercaptopurine toxicity related with NUDT15 and ABCC4 variants in Japanese childhood acute lymphoblastic leukemia].
    Tanaka Y
    Rinsho Ketsueki; 2017; 58(8):950-956. PubMed ID: 28883280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic evaluation of 6-mercaptopurine-mediated toxicity in pediatric acute lymphoblastic leukemia patients from a South Indian population.
    Ramalingam R; Kaur H; Scott JX; Sneha LM; Arun Kumar GP; Srinivasan A; Paul SF
    Pharmacogenomics; 2021 May; 22(7):401-411. PubMed ID: 33876659
    [No Abstract]   [Full Text] [Related]  

  • 15. Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.
    Tanaka Y; Nakadate H; Kondoh K; Nakamura K; Koh K; Manabe A
    Pharmacogenomics J; 2018 Apr; 18(2):275-280. PubMed ID: 28418010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
    Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
    J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
    Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M
    Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.
    Dokmanovic L; Urosevic J; Janic D; Jovanovic N; Petrucev B; Tosic N; Pavlovic S
    Ther Drug Monit; 2006 Dec; 28(6):800-6. PubMed ID: 17164697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia.
    Wojtuszkiewicz A; Barcelos A; Dubbelman B; De Abreu R; Brouwer C; Bökkerink JP; de Haas V; de Groot-Kruseman H; Jansen G; Kaspers GL; Cloos J; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):422-33. PubMed ID: 24940700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL.
    Dorababu P; Naushad SM; Linga VG; Gundeti S; Nagesh N; Kutala VK; Reddanna P; Digumarti R
    Pharmacogenomics; 2012 Jul; 13(9):1001-8. PubMed ID: 22838948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.